Patients who were monitored between January 2012 and June 2013 and whose indication for monitoring was TIA or stroke (data obtained from manufacturer of ZioPatch)Ībout 15% of first paroxysmal atrial fibrillation episodes occurred after 48 h and thus were detected by ZioPatch only.Ītrial fibrillation was defined as RR irregularity for more than 30 sĭischarged adult Emergency department patients with symptoms of arrhythmia 0001) but there were additional arrhythmia events detected by ZioPatch because of longer wear duration. Patients with paroxysmal AF referred for Holter monitoring for detection of arrhythmiasĪtrial fibrillation was defined as the absence of distinct P waves and irregular RR interval.ĭuring first 24 h, mean atrial fibrillation detection by Holter and ZioPatch was comparable ( P <. Healthy volunteers and hospitalized patients in sinus rhythm on dofetilide or sotalolĪlivecor is accurate in measuring QTc interval ( P 4 beats), atrial fibrillation/flutter (>4 beats), pause >3 s, atrioventricular block (Mobitz type II or third‐degree atrioventricular block), ventricular tachycardia (>4 beats), or polymorphic ventricular tachycardia/ventricular fibrillationĭata from the device manufacturer (iRhythm Technologies) for patients who had completed ZioPatch monitoring for clinical indications from January 1, 2011, to December 31, 2011.ĭiagnostic yield of arrhythmia detection by ZioPatch was greater when taken for the entire wear duration compared with the first 48‐h Holter monitor ( P 3 s, second‐degree Mobitz II or complete AV block, SVT, VT, and symptomatic bradycardia. Pharmacy customers aged ≥65 y (mean 76 ± 7 y 44% male) were screened. Patients with hypertension, with diabetes mellitus, and/or aged ≥65 y were recruited. To distinguish this technology from conventional electrocardiography that could have been performed in an out‐of‐hospital setting, we focused only on portable, handheld, or wearable devices.Ītrial fibrillation was defined as absent P wave and RR interval irregularity on ECG Diagnostic accuracy of the devices is represented in Table 1 and utility (pros and cons) in Table 2. We performed this review to understand the current state of out‐of‐hospital electrocardiography technologies with respect to diagnostic accuracy and utility. More visits to a hospital because of a false‐positive test, and missed opportunities because of false negatives will always be a concern as this technology expands. As information obtained by ECG invariably needs to be interpreted along with clinical inputs, it is debated if out‐of‐hospital use will really be beneficial. Hence, concerns about their accuracy and reliability need to be examined. 8 Many handheld ECG devices give only limited information as compared to conventional 12‐lead ECGs. 6, 7 Many such sensors are wearable, small in size, and can be used to monitor rhythms and waveforms over weeks or months. It is also possible to immediately transmit obtained waveforms for expert interpretation, in addition to already available computerized reports. This advancement has a potential to enhance utility of this technique in out‐of‐hospital settings such as within households, endurance trainings, sports training, and public places. Many such technologies are wearable and can record cardiac impulses for extended periods of time. Innovations in sensor technologies have made it possible to record electric impulses from heart in the absence of conventional ECG machines. The diagnostic yield is increased by 15% to 39% by a 24‐hour recording. 4 Evaluation of cardiac rhythm for extended periods of time is rewarding for detection of arrhythmias. 3 In addition, ECG changes also suggest abnormalities in cardiac chambers, serum electrolyte levels, and certain drug toxicities. ECG is useful as in the presence of acute chest pain as ST‐segment elevation suggests myocardial ischemia in more than 90% instances, 2 and ST depression in more than 60% instances. Performing electrocardiography (ECG), a modality that can detect life‐threatening conditions (such as ventricular or atrial arrhythmias, or ischemic changes in the ST segment), is used in healthcare facilities for initial assessment of such symptoms. 1 Early recognition of cardiovascular manifestations such as angina, dyspnea, palpitations, and syncope is emphasized, and patients with such symptom need to visit their doctors for evaluation. Cardiovascular diseases (CVDs) are leading cause of mortality worldwide, accounting for 17.3 million deaths per year, a number that is expected to grow to more than 23.6 million by 2030.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |